Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Cheifetz

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Alimentary Pharmacology & Therapeutics|January 9, 2010
Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's diseaseG A Doherty, G C Bennett, A S Cheifetz, et al.
Journal of Crohn'S & Colitis|July 23, 2014
A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndromeJ D Feuerstein, S N Flier, E U Yee, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2008
The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's diseaseA C Moss, N Fernandez-Becker, K Jo Kim, et al.
Alimentary Pharmacology & Therapeutics|March 11, 2014
The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitisJ L Pleet, B P Vaughn, J A Morris, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2013
Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelinesJ D Feuerstein, M Akbari, A E Gifford, et al.
Alimentary Pharmacology & Therapeutics|February 26, 2013
The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndromeC Lahiff, P Safaie, A Awais, et al.
United European Gastroenterology Journal|March 25, 2026
Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel DiseaseX Roblin, S Nancey, K Papamichael, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2018
Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014S Ballou, W Hirsch, P Singh, et al.
Inflammatory Bowel Diseases|February 17, 2012
Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groupsA S Cheifetz, G Y Melmed, B Spiegel, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Alimentary Pharmacology & Therapeutics|January 9, 2010
Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's diseaseG A Doherty, G C Bennett, A S Cheifetz, et al.
Journal of Crohn'S & Colitis|July 23, 2014
A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndromeJ D Feuerstein, S N Flier, E U Yee, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2008
The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's diseaseA C Moss, N Fernandez-Becker, K Jo Kim, et al.
Alimentary Pharmacology & Therapeutics|March 11, 2014
The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitisJ L Pleet, B P Vaughn, J A Morris, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2013
Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelinesJ D Feuerstein, M Akbari, A E Gifford, et al.
Alimentary Pharmacology & Therapeutics|February 26, 2013
The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndromeC Lahiff, P Safaie, A Awais, et al.
United European Gastroenterology Journal|March 25, 2026
Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel DiseaseX Roblin, S Nancey, K Papamichael, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2018
Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014S Ballou, W Hirsch, P Singh, et al.
Inflammatory Bowel Diseases|February 17, 2012
Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groupsA S Cheifetz, G Y Melmed, B Spiegel, et al.
Pageof 2